Thymosin Alpha-1 Dosage Chart, Schedule & Reconstitution Protocol

Mechanism of Action (MOA)

Thymosin Alpha-1 (Tα1, thymalfasin) is a 28-amino-acid acetylated peptide (Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN) with a molecular weight of approximately 3,108 Da, originally isolated by Allan Goldstein and colleagues from bovine thymus fraction V in 1972 and subsequently synthesized chemically. Endogenous Tα1 is produced by cleavage of the precursor protein prothymosin α and is secreted by thymic epithelial cells, where it contributes to T-cell maturation. Recombinant or chemically synthesized Tα1 is identical to the natural peptide and is marketed worldwide as Zadaxin (thymalfasin) for chronic hepatitis B, chronic hepatitis C, immune adjunct in cancer and infection, and influenza vaccination enhancement in elderly populations [1]. Mechanistically, Tα1 functions as an endogenous immunomodulator that bridges innate and adaptive immunity through several pathways. First, Tα1 binds Toll-like receptor 9 (TLR-9) and TLR-2 on plasmacytoid and myeloid dendritic cells, activating MyD88-dependent signaling and inducing maturation of dendritic cells with upregulation of CD80, CD86, MHC class II, and type I interferon production. Mature dendritic cells then prime naïve T cells toward Th1 differentiation, with downstream production of IFN-γ, IL-2, and IL-12, supporting cell-mediated immunity against intracellular pathogens and tumor cells [2]. Second, Tα1 modulates regulatory T cells (Tregs). At lower doses, Tα1 expands Treg populations and contributes to immune tolerance and resolution of inflammation; at higher doses or in the context of established malignancy, Tα1 can shift the balance toward effector T cell function. This dual capacity for promoting tolerance or effector immunity depending on context underlies its therapeutic use in both chronic viral infection (where immune exhaustion limits clearance) and sepsis (where dysregulated inflammation drives organ damage). Third, Tα1 restores natural killer (NK) cell cytotoxicity and CD8+ cytotoxic T-cell activity in immunocompromised states. In HIV, chronic viral hepatitis, and cancer, NK and CD8 function is often suppressed, and Tα1 supplementation restores antiviral and antitumor cytotoxicity in clinical and laboratory studies. Fourth, Tα1 has direct effects on apoptosis, oxidative stress, and inflammation independent of immune cell signaling, including inhibition of pulmonary fibrosis-associated TGF-β signaling and modulation of NF-κB activity in inflammation [3]. Clinically, the standard Tα1 dosing regimen is 1.6 mg administered subcutaneously twice per week for chronic hepatitis B (over 26 weeks) or chronic hepatitis C (over 24 weeks combined with pegylated interferon and ribavirin). For sepsis, Tα1 has been administered every twelve hours for seven days at 1.6 mg subcutaneously in the multicenter ETASS trial conducted by Wu and colleagues, with results suggesting reductions in 28-day mortality compared with placebo in subgroup analyses, although the primary endpoint was not met [4]. In cancer immunotherapy, Tα1 has been studied as an adjunct to dacarbazine in melanoma, gemcitabine in pancreatic cancer, and immune checkpoint inhibitors more recently. Pharmacokinetic studies show rapid subcutaneous absorption with peak plasma concentrations at one to two hours and an elimination half-life of approximately two hours, with circulating Tα1 levels transiently increased 50–100 times normal after a single 1.6 mg dose [1]. The FDA has granted orphan drug status for thymalfasin for stage 2B–4 malignant melanoma (2006) and hepatocellular carcinoma, but full marketing approval in the United States has not been granted. Tα1 is approved in more than thirty-five countries for chronic viral hepatitis and as an immune adjunct. Camerini, Garaci, Goldstein, and other authors have repeatedly described Tα1 as virtually devoid of toxicity, with adverse events comparable to placebo in randomized trials [5].